WO2014115087A3 - Procédé de préparation de prothrombine et de fibrinogène humains recombinants - Google Patents
Procédé de préparation de prothrombine et de fibrinogène humains recombinants Download PDFInfo
- Publication number
- WO2014115087A3 WO2014115087A3 PCT/IB2014/058465 IB2014058465W WO2014115087A3 WO 2014115087 A3 WO2014115087 A3 WO 2014115087A3 IB 2014058465 W IB2014058465 W IB 2014058465W WO 2014115087 A3 WO2014115087 A3 WO 2014115087A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recombinant human
- fibrinogen
- preparation
- human prothrombin
- coagulation factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne un procédé de production d'un facteur de coagulation humain. En particulier, le facteur de coagulation est produit dans une cellule hôte humaine. L'invention concerne également l'utilisation du facteur de coagulation humain recombinant en médecine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015135227A RU2015135227A (ru) | 2013-01-22 | 2014-01-22 | Способ получения рекомбинантного человеческого протромбина и фибриногена |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361849208P | 2013-01-22 | 2013-01-22 | |
US61/849,208 | 2013-01-22 | ||
US201361851801P | 2013-03-13 | 2013-03-13 | |
US61/851,801 | 2013-03-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014115087A2 WO2014115087A2 (fr) | 2014-07-31 |
WO2014115087A3 true WO2014115087A3 (fr) | 2014-10-30 |
Family
ID=50102145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/058465 WO2014115087A2 (fr) | 2013-01-22 | 2014-01-22 | Procédé de préparation de prothrombine et de fibrinogène humains recombinants |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2015135227A (fr) |
WO (1) | WO2014115087A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3359145A4 (fr) * | 2015-10-09 | 2019-03-20 | Cleveland State University | Analogues de la prothrombine recombinante et utilisations de ceux-ci |
EP3916009B1 (fr) * | 2020-05-26 | 2023-06-28 | Sartorius Lab Instruments GmbH & Co. KG | Protéines recombinantes basées sur du fibrinogène |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1661989A1 (fr) * | 2003-07-29 | 2006-05-31 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Procede pour preparer une cellule de recombinaison qui presente une grande capacite de production de fibrinogene et cellule presentant une grande capacite de production de fibrinogene |
WO2007103447A2 (fr) * | 2006-03-06 | 2007-09-13 | Humagene, Inc. | Procede de preparation de la thrombine recombinante humaine et du fibrinogene |
DE102009003439A1 (de) * | 2009-02-05 | 2010-08-26 | Cevec Pharmaceuticals Gmbh | Neue permanente humane Zelllinie |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE20824T1 (de) | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundheilung. |
US4442655A (en) | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
JPS6144825A (ja) | 1984-08-09 | 1986-03-04 | Unitika Ltd | 止血剤 |
US4965203A (en) | 1987-01-28 | 1990-10-23 | Warner-Lambert Company | Purified thrombin preparations |
US5572692A (en) | 1991-12-24 | 1996-11-05 | Intel Corporation | Memory configuration decoding system having automatic row base address generation mechanism for variable memory devices with row access interleaving |
US5527692A (en) | 1991-12-31 | 1996-06-18 | Zymogenetics, Inc. | Methods for producing thrombin |
US5476777A (en) | 1991-12-31 | 1995-12-19 | Zymogenetics, Inc. | Methods for producing thrombin |
US6780411B2 (en) | 1998-05-01 | 2004-08-24 | Zymogenetics, Inc. | Tissue sealant compositions |
DE102005054628A1 (de) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
EP2729190B1 (fr) | 2011-07-10 | 2015-09-09 | Coloplast A/S | Utilisation de la thrombine pour cicatriser les plaies |
-
2014
- 2014-01-22 WO PCT/IB2014/058465 patent/WO2014115087A2/fr active Application Filing
- 2014-01-22 RU RU2015135227A patent/RU2015135227A/ru unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1661989A1 (fr) * | 2003-07-29 | 2006-05-31 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Procede pour preparer une cellule de recombinaison qui presente une grande capacite de production de fibrinogene et cellule presentant une grande capacite de production de fibrinogene |
WO2007103447A2 (fr) * | 2006-03-06 | 2007-09-13 | Humagene, Inc. | Procede de preparation de la thrombine recombinante humaine et du fibrinogene |
DE102009003439A1 (de) * | 2009-02-05 | 2010-08-26 | Cevec Pharmaceuticals Gmbh | Neue permanente humane Zelllinie |
Non-Patent Citations (2)
Title |
---|
MARIA G. ROUBELAKIS ET AL: "Amniotic Fluid and Amniotic Membrane Stem Cells: Marker Discovery", STEM CELLS INTERNATIONAL, vol. 1, no. 1, 1 January 2012 (2012-01-01), pages 42 - 9, XP055111310, ISSN: 1687-966X, DOI: 10.1128/IAI.00643-07 * |
SIMON FISCHER ET AL: "ARTICLE Transient Recombinant Protein Expression in a Human Amniocyte Cell Line: The CAP-T 1 Cell System", BIOTECHNOL. BIOENG, 1 January 2012 (2012-01-01), pages 2250 - 2261, XP055111266, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1002/bit.24514/asset/24514_ftp.pdf?v=1&t=hth4zx74&s=6f41e7d8e53831e1f47db696e8f5c5d5436cea5a> [retrieved on 20140401] * |
Also Published As
Publication number | Publication date |
---|---|
WO2014115087A2 (fr) | 2014-07-31 |
RU2015135227A (ru) | 2018-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501703A1 (en) | Trifluormethyl-substituted ring-fused pyrimidines and use thereof | |
TN2015000434A1 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
IL288265A (en) | Production and use of red blood cells | |
WO2013151666A3 (fr) | Polynucléotides modifiés destinés à la production de produits biologiques et de protéines associées à une maladie humaine | |
CN104812762A8 (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
PH12014501595A1 (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
WO2013151665A3 (fr) | Polynucléotides modifiés destinés à la production de protéines associées à une maladie humaine | |
WO2014151878A3 (fr) | Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides | |
BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
MY164356A (en) | Substituted 5-fluoro-1h-pyrazolopyridines and their use | |
WO2012106407A3 (fr) | Procédés diagnostiques et thérapeutiques et produits liés aux troubles de l'anxiété | |
MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
PH12014502496B1 (en) | Bicyclically substituted uracils and the use thereof | |
PH12015500636A1 (en) | Nutritional compositions including a calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes | |
AU2013359031A8 (en) | Methods and apparatuses for making pasta filata | |
EA201600096A1 (ru) | Бензил-1н-пиразол[3,4-b]пиридины и их применение | |
MD20150109A2 (ro) | Construcţii proteice mitocondriale şi utilizările acestora | |
MX2016003588A (es) | Derivados de fenilalanina sustituidos. | |
PH12016500608A1 (en) | Cyclic thienouracil-carboxamides and use thereof | |
WO2014115087A3 (fr) | Procédé de préparation de prothrombine et de fibrinogène humains recombinants | |
WO2013109190A3 (fr) | Expression de protéine recombinante cho-gmt | |
AU2011301714B2 (en) | Synthetic gene for expressing Sm-14 in Pichia pastoris, methods for producing and purifying Sm-14 and the use thereof as a vaccine and diagnostic medium | |
IL234087A0 (en) | The composition of an ascorbic acid derivative and a method for its production, a solution of an ascorbic acid derivative and an external preparation for the skin | |
TN2015000523A1 (en) | Substituted benzoxazoles | |
TN2014000085A1 (en) | Substituted annellated pyrimidine and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14704395 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2015135227 Country of ref document: RU Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14704395 Country of ref document: EP Kind code of ref document: A2 |